spec sheet6 rows
Clemastine is a first generation ethanolamine antihistamine used for allergic rhinitis, urticaria and itch, and it sedates.
- Established antihistamine for allergic rhinitis, urticaria and itch
- First generation ethanolamine that reaches into the brain
- Sedating, which suits night time itch and sleep
- Early remyelination research in multiple sclerosis made it famous
- Muscarinic action studied on oligodendrocyte precursor cells
- A cheap, familiar generic with decades of clinical use
- Clemastine was identified as a remyelinating agent by an unbiased micropillar high-throughput screen, not by rational design; the active property turned out to be its muscarinic antagonism, not its antihistamine activity [3].
- ReBUILD is the reason anyone outside allergy medicine knows this drug: 50 patients with relapsing MS and chronic demyelinating optic neuropathy, crossover design, 5.36 mg twice daily, and it met its primary endpoint with a 1.7 ms/eye shortening of VEP P100 latency (95% CI 0.5-2.9, P=0.0048). It remains the first randomised trial to document efficacy of a remyelinating drug [1].
- The honest caveat is that ReBUILD's effect size is small, the endpoint is electrophysiological rather than clinical, no disability benefit was shown, and fatigue was the notable adverse effect.
- The critical newer finding is a harm signal: in the TRAP-MS platform trial the clemastine arm was stopped early when 3 of 9 patients with progression independent of relapse activity triggered individual safety stopping criteria, and clemastine-treated patients had significantly faster disability progression than other participants. CSF proteomics showed increased purinergic signalling and pyroptosis, and mechanistic work showed clemastine plus extracellular ATP kills macrophages and human oligodendrocytes by pyroptosis via P2RX7 [2].
- Preclinical evidence is genuinely mixed, not uniformly positive: clemastine promotes myelin repair in a non-human primate model with no spontaneous remyelination [4], but it also impairs developmental myelination in young animals [5], which is a real concern for anyone young taking it off-label.
- The cognition angle that draws nootropics readers rests on animal work such as rescue of chemotherapy-induced cognitive impairment via white matter integrity [6]; there is no randomised human trial showing clemastine improves cognition in healthy people.
Mechanism
It blocks H1 receptors and crosses into the brain, where the same blockade produces drowsiness; it is also antimuscarinic, which accounts for the dry mouth, blurred vision and urinary hesitancy. Separately it has drawn research interest as a remyelinating agent in multiple sclerosis, an effect attributed to blockade on oligodendrocyte precursor cells rather than to anything histaminergic.
receptor fingerprint
H1 receptor (HRH1)Antagonist / inverse agonist; clemastine is among the most potent H1 antagonists ever characterised
receptor M1 (CHRM1)Antagonist; M1 blockade on oligodendrocyte precursor cells is the proposed remyelination mechanism
receptors M3, M4 and M5Antagonist
Oligodendrocyte precursor cell differentiation and myelinationEnhanced; identified in a micropillar high-throughput screen and confirmed in rodent and non-human primate demyelination models
P2RX7 purinergic receptor and inflammasome-dependent pyroptosisClemastine plus sublytic extracellular ATP activates the inflammasome and induces pyroptotic death of macrophages and of human iPSC-derived oligodendrocytes; blocked by P2RX7 antagonism
Safetyrisks and cautions, not medical advice
Clemastine is a single molecule in the antihistamine class. A full adverse effect profile has not been compiled for this entry yet, so nothing here should be read as evidence that it is well tolerated; the absence is missing work rather than a finding. What is documented is what the compound is and what it is used for.
Subjective profileweighing the evidence above
Remyelination is the only reason anyone outside an allergy clinic has heard of this, and it is not a reason to buy it. The effect attributed to muscarinic blockade on oligodendrocyte precursors is an early finding in multiple sclerosis rather than an established treatment, and the same antimuscarinic activity produces the dry mouth, blurred vision and urinary hesitancy. As an antihistamine it is ordinary and outclassed by the non sedating options for daytime allergy. Long term anticholinergic exposure is the caveat that matters most, particularly in older adults, where it is associated with cognitive harm.
Where to buy
Suppliers
Vendors carrying Clemastine, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
RUPharma🌐
Clemastine
Research
- 2014first citedMicropillar arrays as a high-throughput screening platform for therapeutics in multiple scleros…
- 2017controlled trialClemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised,…
- 2026most recentClemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination charact…
- 1.Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial.
- 2.Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis.
- 3.Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
- 4.Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination.
- 5.Clemastine Induces an Impairment in Developmental Myelination.
- 6.Clemastine Rescues Chemotherapy-Induced Cognitive Impairment by Improving White Matter Integrity.
- 7.Interventions promoting remyelination in multiple sclerosis: a systematic review of clinical trials.
- 8.Drug repurposing: Clemastine fumarate and neurodegeneration.
8 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
Notes and cautions
- Clemastine is a first-generation antihistamine and it sedates heavily; the remyelination dose used in ReBUILD, 5.36 mg twice daily, is far above the usual antihistamine dose and fatigue was the main adverse effect even in that trial [1].
- It carries a substantial anticholinergic burden through M1, M3, M4 and M5 blockade, which means dry mouth, urinary retention, constipation and blurred vision, and which makes chronic use a poor idea in older adults given the association between long-term anticholinergic exposure and cognitive decline.
- The most important recent finding is a safety one: the clemastine arm of the TRAP-MS trial was stopped early because patients with progressive MS accumulated disability faster on the drug, with a proposed P2RX7-inflammasome pyroptosis mechanism [2], so self-experimentation in progressive MS is not a neutral act.
- Animal data also show impaired developmental myelination [5], which argues against use in children and adolescents.
- Sedation is additive with alcohol, opioids and benzodiazepines.